UNIVERSITY OF MICHIGAN

Ascentage Pharma announced that APG-2449, a FAK/ALK/ROS1 TKI, has been cleared by China's NMPA to enter two Phase III studies for NSCLC patients resistant to or naïve to ALK TKIs. APG-2449 showed preliminary efficacy and safety, with potential to inhibit brain metastases, addressing unmet needs in NSCLC treatment.

Benjamin Pockros, MD, MBA, discusses implementing prostate MRI without contrast in active surveillance protocols, highlighting financial benefits and reduced treatment side effects. At the University of Michigan, they've begun offering this MRI variant for active surveillance patients and plan to study its impact.

Engineered nonpathogenic E. coli displaying decoy-resistant IL18 show potent anti-tumor responses, boosting CAR-NK cell therapy and demonstrating safety in hard-to-treat tumors.

Engineered nonpathogenic E. coli expressing immune-activating cytokines on their surfaces demonstrated potent anti-tumor responses and enhanced CAR-NK cell therapy efficacy, with a 50-60% cure rate in mice, suggesting potential as a 'tumor GPS' for NK cells.

FDA grants 510(k) clearance for an automated Monte Carlo dosimetry method, enabling rapid radiotherapy dose planning in seconds via the MIM SurePlan MRT platform. This advancement allows for quicker, more accurate patient-specific dosimetry, potentially improving radiopharmaceutical therapy outcomes.

GE HealthCare's MIM Software received FDA 510(k) clearance for Monte Carlo dosimetry using the Dose Planning Method (DPM) in MIM SurePlan MRT, enabling fast, accurate absorbed dose calculation for personalized Theranostics treatments without additional hardware.

GE HealthCare’s MIM Software received FDA 510(k) clearance for Monte Carlo dosimetry, enabling accurate radionuclide absorbed dose calculations in theranostics, enhancing personalized cancer care.

FDA delays release of guidelines to improve pulse oximeter accuracy for patients with darker skin, despite evidence of inaccuracies leading to treatment disparities and deaths. Physicians and health equity advocates criticize the FDA's slow response, calling for stricter testing and clearer labeling to address racial biases in medical devices.

A workshop on disability trends among U.S. working-age populations (25-64) will be held Oct 15-16, 2024, focusing on measurement, social/economic factors, and COVID-19 implications. It aims to identify research and data priorities, considering labor force participation and public programs, and will discuss interventions and social safety net policies.